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Abstract objective The microbiologic causes of bloodstream infections (BSI) may differ between HIV-
positive and HIV-negative patients and direct initial empiric antibiotic treatment (i.e. treatment
before culture results are available). We retrospectively assessed community-acquired BSI episodes in
adults in Cambodia according to HIV status for spectrum of bacterial pathogens, antibiotic resistance
patterns and appropriateness of empiric antibiotics.
methods Blood cultures were systematically performed in patients suspected of BSI in a referral
hospital in Phnom Penh, Cambodia. Data were collected between 1 January 2009 and 31 December
2011.
results A total of 452 culture-conﬁrmed episodes of BSI were recorded in 435 patients, of whom
17.9% and 82.1% were HIV-positive and HIV-negative, respectively. Escherichia coli accounted for
one-third (n = 155, 32.9%) of 471 organisms, with similar rates in both patient groups.
Staphylococcus aureus and Salmonella cholereasuis were more frequent in HIV-positive vs. HIV-
negative patients (17/88 vs. 38/383 (P = 0.02) and 10/88 vs. 5/383 (P < 0.001)). Burkholderia
pseudomallei was more common in HIV-negative than in HIV-positive patients (39/383 vs. 2/88,
P < 0.001). High resistance rates among commonly used antibiotics were observed, including 46.6%
ceftriaxone resistance among E. coli isolates. Empiric antibiotic treatments were similarly appropriate
in both patient groups but did not cover antibiotic-resistant E. coli (both patient groups), S. aureus
(both groups) and B. pseudomallei (HIV-negative patients).
conclusion The present data do not warrant different empiric antibiotic regimens for HIV-positive
vs. HIV-negative patients in Cambodia. The overall resistance rates compromise the appropriateness
of the current treatment guidelines.
keywords Bloodstream infection, human immunodeﬁciency virus(HIV), adult, Cambodia
Introduction
Bloodstream infection (BSI) is an important cause of
morbidity and mortality worldwide (Becker et al. 2009).
For successful management of BSI, appropriate antimicro-
bial treatment is required, and the choice of the initial
empiric antibiotic regimen (i.e. antibiotics given before
the results of microbiological diagnosis and susceptibility
testing are available) is particularly important (Houck
et al. 2004; Garnacho-Montero et al. 2006; Kumar et al.
2006). The choice of empiric antibiotics relies on
accurate knowledge of bacterial pathogens prevalent in
a speciﬁc location and on their resistance patterns
(Ibrahim et al. 2000).
For the management of BSI, clinical practice guidelines
for empiric antimicrobial treatment have been written
and implemented since January 2009 in the Sihanouk
Hospital Center of HOPE (SHCH), a referral hospital in
the capital Phnom Penh, Cambodia. These guidelines
were based at that time on a literature review and a preli-
minary analysis of 18-months surveillance data of antimi-
crobial resistance in the hospital. However, these
guidelines had not yet been validated in the patient
population attending SHCH. In addition, published data
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in patients infected with the human immunodeﬁciency
virus (HIV) in Cambodia are lacking.
Patients infected with HIV are at increased risk of bac-
terial infections with case-fatality rates of up to 32% in
patients with CD4 counts less than 200 cells/ll (Tumba-
rello et al. 1995; Perello et al. 2010). Moreover, many
HIV-positive patients are given primary cotrimoxazole
(trimethoprim/sulphamethoxazole) prophylaxis, and
exposure to this antibiotic might increase the risk of anti-
biotic resistance in a variety of bacterial pathogens that
may infect this high-risk population (Gill et al. 2004).
The SHCH treatment guidelines for BSI are not differ-
ent for HIV-positive vs. HIV-negative patients. The HIV
prevalence in Cambodia in the general population was
estimated at 0.8% in 2010 (NCHADS 2011). However,
as SHCH also has a large HIV treatment programme,
HIV-positive patients account for about 20% of the
blood cultures performed in SHCH. In studies from sub-
Saharan Africa and Thailand, HIV-positive patients pre-
senting with BSI often had different bacterial pathogens
and antibiotic resistance proﬁles compared with those
who were HIV-negative (Ssali et al. 1998; Mootsikapun
2007). Therefore, empiric antibiotic treatment recommen-
dations of the current SHCH guidelines might not be
appropriate for HIV-positive patients.
The aim of this study was to determine, in adult
patients presenting at SHCH with community-acquired
BSI and stratiﬁed according to HIV status (i) the bacterial
pathogens identiﬁed, (ii) their proﬁle of antibiotic resis-
tance, and (iii) the appropriateness of current empiric
antibiotic treatments.
Method
Study design
This was a retrospective study using data prospectively
collected into a logbook of the surveillance of BSI in
SHCH between 1 January 2009 and 31 December 2011.
Study site
The SHCH is a referral hospital operated by a non-gov-
ernmental organisation, situated in the Cambodian capi-
tal, Phnom Penh. Cambodia is a low-income country in
South-East Asia with a population of around 14 million
inhabitants.
SHCH provides free care to poor adult patients, includ-
ing treatment of opportunistic infections and antiretrovi-
ral treatment (ART) for HIV-positive adult patients. The
hospital has 35 in-patient beds and annually about 1 500
patients are admitted through self-referrals or referrals
from other healthcare facilities nationwide. It also treats
approximately 120 000 outpatients annually. By Decem-
ber 2011, more than 3 200 HIV-positive patients were
alive in the cohort of patients cared for in the hospital, of
whom 2 900 were eligible for ART and currently on
treatment.
Since 2007, SHCH has implemented, in collaboration
with the Institute for Tropical Medicine (ITM), Antwerp,
Belgium, a surveillance of antimicrobial resistance by per-
forming systematic blood cultures in all patients seen at
the hospital and suspected of BSI. This collaboration has
resulted in the development of clinical practice guidelines
for the management of BSI, with recommendations for
empiric and culture-based antimicrobial treatment. An
antibiotic surveillance logbook was created to record all
patients having a positive blood culture with clinically
signiﬁcant pathogens.
HIV treatment and care
Voluntary conﬁdential counselling and testing for HIV
(VCCT) is available at the hospital for patients presenting
to the outpatient department or admitted to the wards
and is recommended if clinicians suspect HIV infection.
HIV screening is carried out using a parallel system with
two rapid tests [Determine (Determine, Inverness Medi-
cal, Japan) and HIV-1/2 Stat-Pak (Chembio Diagnostics,
USA)], and if there are discordant results, an ELISA test
is used to conﬁrm the diagnosis. CD4-lymphocyte counts
are measured at baseline and every 6 months using a
FACScount (Becton Dickinson, Franklin Lakes, NJ). ART
is provided in line with WHO guidelines (CD4  350/ll
or WHO Clinical Stage 4 disease, and recently, WHO
Clinical Stage 3 disease, regardless of the CD4 cell count)
(WHO 2010).
Bloodstream infection surveillance and antibiotic
treatment
Blood cultures are systematically carried out in all
patients (HIV-positive and HIV-negative) who present
with systemic inﬂammatory response syndrome (SIRS).
SIRS is deﬁned as the presence of at least two of the fol-
lowing signs: fever/hypothermia (temperature <35 or
>38 °C), tachycardia (heart rate >90 beats/min), tachyp-
nea (respiratory rate >20/min) and hypo- or hyper-leuko-
cytosis (white cells count <4 000 or >12 000/ll). In each
patient, 2 9 10 ml of venous blood is drawn into
BacTalert vials (bioM erieux Marcy l’Etoile, France) and
incubated for 7 days at 35 °C while visual inspection of
the chromogenic growth indicator is used for growth
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using standard microbiological techniques. Antibiotic
resistance testing is performed using disc diffusion with
the additional use of the E-test (bioM erieux) for penicil-
lin in Streptococcus pneumoniae and double-disc testing
for extended-spectrum beta-lactamase (ESBL) production.
Nalidixic acid resistance is used as a screening test for
decreased ciproﬂoxacin susceptibility. All tests are per-
formed according to Clinical Laboratory Standards Insti-
tute guidelines (CLSI 2012).
Patients with suspected BSI are treated with empiric
antibiotics according to the SHCH guidelines. These
guidelines are the same for HIV-positive and HIV-nega-
tive patients, except when Pneumocystis jiroveci pneu-
monia is suspected. When blood culture results are
available, clinicians modify the empiric antibiotics
according to the pathogen or its resistance pattern. If
patients are not hospitalised, they are contacted by tele-
phone. The liaison between the laboratory and the clini-
cal wards is assured by two appointed clinicians who
keep records in the logbook. This logbook contains
basic demographic and clinical information as well as
changes in antibiotic therapy and patients’ outcome at
discharge or at the end of treatment for ambulatory
patients (at 7–14 days). The quality of the logbook data
is routinely checked at regular intervals by an infectious
diseases supervisor.
Study participants and study period
All adult patients aged 18 years or above with conﬁrmed
BSI based on positive blood culture seen in the SHCH
and recorded between January 2009 and December 2011
were included. As the guidelines were essentially devel-
oped to guide treatment of community-acquired infec-
tions, BSIs that were hospital-acquired (occurring 48 h
after admission) were excluded.
Deﬁnition of BSI episode and recurrent infection
We identiﬁed BSI as the presence of a clinically signiﬁcant
pathogen isolated from blood cultures. Isolates consid-
ered as contaminants were coagulase negative staphylo-
cocci, Bacillus species and Corynebacterium species.
Repeat culture of an identical pathogen (same species
and/or serotype) was considered as follows: if the repeat
culture was performed within 14 days after the ﬁrst one,
both isolates were considered to be part of a single BSI
episode; if the repeat culture was performed more than
14 days after the initial one, the repeat isolate was
considered as part of a new BSI and called a recurrent
infection.
Source of data, data variables and validation and data
collection
The following variables were collected from the log-
book: demographic data (age, sex), suspected focus of
infection, duration of hospitalisation prior to sample
collection, HIV status and other comorbidities, antiretro-
viral drugs used, empiric antibiotic treatment given, ﬁnal
bacterial identiﬁcation, antibiotic resistance patterns,
appropriateness of empiric antibiotic treatment, any
change in the antibiotic treatment and its rationale, and
outcome.
The appropriateness of empiric antibiotics was deﬁned
as a ‘match’ if the spectrum of the empiric antibiotics
covered the isolated pathogen(s), and no antibiotic resis-
tance had been demonstrated. A mismatch was consid-
ered when (i) if the spectrum of the empiric antibiotic did
not cover the pathogen (such as in the case of amoxicillin
and Burkholderia pseudomallei) or (ii) if the pathogen
showed resistance to the antibiotic (such as in the case of
methicillin-resistant Staphylococcus aureus and oxacillin).
Data analysis and statistics
Data from the logbook were single-entered into EPIDATA
version 3.1 and checked for accuracy by comparing the
logbook and laboratory database. EPIDATA data were
transferred by Stat/Transfer software into STATA version
11.1 for analysis. For demographic and clinical data, we
used as denominator either the number of patients with
BSI or the number of BSI episodes where applicable, and
for microbiological data, the total number of bacteria.
Bacterial resistance rates were calculated using the ‘ﬁrst’
(i.e. non-recurrent) isolates. Descriptive analysis was used
to calculate the frequency and proportion of demographic
and clinical/microbiological data. The chi-squared test or
Fisher’s exact test was used to compare differences in
proportions and t-test for comparing the continuous data
between HIV-positive and HIV-negative patients. All sta-
tistical tests were two sided, and statistical signiﬁcance
was deﬁned as P < 0.05.
Ethics
The data collection was part of the study on ‘surveillance
of antibiotic resistance in the hospital’ which was
approved by the Institutional Review Board ITM (Insti-
tute of Tropical Medicine, Antwerp) and the Cambodian
National Ethics Committee for Health Research. This
protocol was approved by the Ethics Advisory Group of
the International Union Against Tuberculosis and Lung
Disease, Paris, France. Also, this study met the M edecins
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for analysis of routinely collected programme data.
Results
Figure 1 presents a ﬂow chart of the study and the break-
down between HIV-positive and HIV-negative patients.
Overall, 5 457 episodes of community-acquired SIRS
were included, which yielded 452 culture-conﬁrmed
episodes of BSI in 435 patients, of whom 17.9% were
HIV-positive and and 82.1% HIV-negative. The rate of
clinical signiﬁcant organisms did not differ between both
groups. Twenty episodes (4.4%) were polymicrobial; 4
patients had second episodes of BSI with different isolates
and 13 patients had recurrent BSI (one patient had two
recurrences); the resulting total number of clinically
signiﬁcant organisms was 471.
Patient characteristics
Table 1 shows the characteristics of HIV-positive and
HIV-negative patients with BSI. HIV-positive patients
were signiﬁcantly younger and had less comorbidity,
particularly diabetes and liver cirrhosis. Gastrointestinal,
respiratory and urinary tract infections were the three
most common presumed foci of BSI. There were no
differences in the presumed foci between BSI in HIV-
positive vs. HIV-negative patients. For the HIV-positive
patients, median CD4 count was 159 (IQR 45–256)
cells/ll; 51 (60.0%) episodes occurred in patients on
ART, and 22 (25.6%) patients were on cotrimoxazole
prophylaxis. For HIV-positive and HIV-negative patients
combined, exposure to antibiotics prior to blood sam-
pling was seen in 51.8%, with no difference among both
groups.
Aetiology of bloodstream infections
Table 2 displays the relative frequencies of the bacterial
pathogens. Gram-negative pathogens were more common
than Gram-positive bacteria in both HIV-positive and
HIV-negative patients. Staphylococcus aureus was the
most common Gram-positive pathogen, and it was
more frequent in HIV-positive patients (19.3% vs. 9.9%
in HIV-negative patients; P = 0.02). Among the
Gram-negative pathogens, Escherichia coli and
Salmonella choleraesuis were the two leading species in
HIV-positive patients (30.7% and 11.4%, respectively),
whereas Escherichia coli and Burkholderia pseudomallei
were predominant in HIV-negative patients (33.4% and
10.2%, respectively). Ten of 19 Salmonella species
(52.6%) were Salmonella choleraesuis among
5457 episodes of community-
acquired SIRS
85 (8.7%) episodes with grown
blood cultures  
(78 patients) 
Total episodes of SIRS with blood 
culture taken in SHCH 
(Jan 2009 – Dec 2011) 
6090 episodes
642 episodes of 
nosocomial SIRS
367 (8.2%) episodes with 
grown blood cultures  
(357 patients) 
HIV-positive patients 
976 SIRS episodes (17.9%) 
HIV-negative patients 
4481 SIRS episodes (82.1%) 
88 clinically significant 
pathogens 
383 clinically significant 
pathogens 
Figure 1 Flowchart of the patients with
systemic inﬂammatory response syndrome
(SIRS) included in the study, 2009-2011.
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(16.1%) were Salmonella choleraesuis.
Antibiotic resistance patterns
The resistance patterns of the key pathogens are shown in
Table 3. Overall resistance rates for commonly used anti-
biotics were very high, especially among the Gram-nega-
tive pathogens. In particular, we noted in both HIV-
positive and HIV-negative patients high rates (46.4%) of
ceftriaxone resistance in E. coli and very high rates
(87.0%) of decreased ciproﬂoxacin susceptibility in Salmo-
nella typhi. Ciproﬂoxacin susceptibility appeared to be
more preserved in the non-Typhoid Salmonella species.
Staphylococcus aureus infecting HIV-positive patients
tended to display resistance to oxacillin and cotrimoxazole
more frequently.
Appropriateness of empiric antibiotic treatment and
subsequent treatment changes
Overall, the proportions of appropriate empiric treatment
were fairly similar for both patients groups (Table 4a).
There were more mismatches due to resistance in the
HIV-positive group, but this difference did not reach sta-
tistical signiﬁcance. For this type of mismatch, antibiotic-
resistant E coli was the main contributor in both groups
(64.0%; 16/25 and 77.9%; 60/77 of such episodes in
HIV-positive and HIV-negative individuals, respectively).
Mismatch due to the fact that the empiric antibiotic
regimens did not cover the putative pathogen was equally
common in both groups. For HIV-positive individuals,
this most commonly involved BSI with Staphylococcus
aureus (4/16; 25.0%). In HIV-negative individuals,
Burkholderia pseudomallei was most commonly
implicated (26/77; 33.8%), followed by Staphylococcus
aureus (11/64; 17.2%).
Empiric treatment was somewhat more frequently
modiﬁed in HIV-positive than HIV-negative patients,
most commonly because it did not cover the resistance
pattern or the pathogen properly (Table 4b). Of note, of
41 BSI episodes in HIV-positive patients who had
inappropriate empiric antibiotic treatment (mismatches),
13 (31.7%) failed to get modiﬁed treatment (no
antibiotic change) compared with 65 of 152 (42.7%) in
HIV-negative patients. This was because patients died
Table 1 Characteristics of patients with bloodstream infection (BSI) presenting to SHCH according to HIV status, 2009–2011;
(n = 435)
HIV-positive
n = 78
HIV-negative
n = 357 p-value
Sex; n (ratio)
Male: Female 36:42 (0.86) 158:199 (0.79) 0.76
Mean age, years (SD) 40.8 (10.9) 48.1 (16.4) <0.001
Comorbidity; n (%)
Diabetes 3 (3.9) 71 (19.9) <0.001
Liver cirrhosis 2 (2.6) 52 (14.6) 0.002
Chronic renal failure 2 (2.6) 14 (3.9) 0.75
Exposure to antibiotics within 14 days prior to blood culture sampling of BSI episodes*; n (%)
Cotrimoxazole prophylaxis 22/85 (25.6) 0 –
Total exposure to antibiotics 47/85 (55.3) 187/452 (50.9) 0.47
Antiretroviral therapy at the time of BSI; n (%) 51/85 (60.0) NA -
Presumed focus of BSI†; n (%) 102 427 0.63
Gastro-enteric infection 50 (49.0) 193 (45.2)
Respiratory infection 22 (21.6) 84 (19.7)
Urinary tract infection 13 (12.8) 67 (15.7)
Skin and soft tissue infection 14 (13.7) 41 (9.6)
Central nervous system infection 2 (2.0) 18 (4.2)
Fever without clear source 1 (0.8) 8 (1.7)
Osteo-articular infection 0 (0) 8 (1.7)
Deep organ abscess 0 (0) 8 (1.7)
Endocarditis 0 (0) 2 (0.4)
IQR: Inter-quartile range, SD: standard deviation.
*Some patients had more than one episode of BSI.
†Some patients had more than one presumed focus of infection.
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were communicated in 6/13 (46.2%) BSI episodes in
HIV-positive and 44/65 (67.7%) BSI episodes in
HIV-negative patients.
Treatment outcomes
Overall mortality was 21.5% (97/452). As can be seen in
Table 5, there was no difference in patient outcomes at
the end of treatment (as noted at day 7 or day 14), in the
HIV-positive and HIV-negative patients. We found higher
rates of recurrent infections in the HIV-positive group
(10.3% vs. 2.3%; P = 0.003): Five were caused by
Escherichia coli (3.2%; one HIV-positive), 3b ySalmo-
nella choleraesuis (20%; two HIV-positive), four by
Staphylococcus aureus (7.3%; two HIV-positive) and one
by Aeromonas sp. (in an HIV-positive patient).
Discussion
This study describes the prevalence of bacterial pathogens
and their resistance patterns causing BSI in adult patients
with and without HIV. Overall, pathogens and resistance
distribution were fairly similar between the two patient
groups. E. coli was the most common pathogen in both
groups and occurred with comparable frequency. How-
ever, particular pathogens were more prevalent in some
patient groups. Salmonella choleraesuis and S. aureus
were more common in HIV-positive patients, while
B. pseudomallei and Salmonella typhi occurred
predominantly in HIV-negative patients. Possibly, older
age and higher frequency of comorbidity in the
HIV-negative patients might have increased their risk of
melioidosis – the disease caused by B. pseudomallei.
Melioidosis was recently found to be endemic in
Cambodia (Vlieghe et al. 2011a).
In general, Gram-negative pathogens predominated in
our study in both HIV-positive and HIV-negative
patients, as has been described in other studies on BSI in
tropical low-resource settings (Archibald et al. 2000;
Phetsouvanh et al. 2006). In line with our ﬁndings,
studies from Thailand (Srifuengfung et al. 2005;
Mootsikapun 2007) also reported a high prevalence of
Salmonella species in HIV-positive patients and of Burk-
holderia pseudomallei in HIV-negative patients. How-
ever, in the Thai studies, E. coli occurred less frequently
in HIV-positive patients, while we found this isolate the
most common cause of BSI in both HIV-positive and
HIV-negative patients. A recent systematic review of BSI
in developing countries in South and South-East Asia,
mainly including HIV-negative individuals, also reported
a high proportion of Gram-negative isolates of which
Salmonella typhi was the most common pathogen in
adults patients (Deen et al. 2012). The predominance of
Gram-negative pathogens contrasts with reports from
North America and European BSI studies in HIV-positive
patients, where Gram-positive bacteria were more
common (Fichtenbaum et al. 1995; Ortega et al. 2008).
Table 2 Distribution of bacterial pathogens causing bloodstream infection according to HIV status in SHCH, 2009–2011 (n = 471)
Organisms HIV-positive; n (%) (n = 88) HIV-negative; n (%) (n = 383)
Gram-negative bacteria
Escherichia coli 27 (30.7) 128 (33.4)
Salmonella choleraesuis 10 (11.4) 5 (1.3)
Other Non-Typhoid Salmonella species 6 (6.8) 3 (0.8)
Salmonella typhi 2 (2.3) 21 (5.5)
Salmonella paratyphi A 0 2 (0.5)
Klebsiella species 5 (5.7) 28 (7.3)
Enterobacter species 3 (3.4) 4 (1.0)
Burkholderia pseudomallei 2 (2.3) 39 (10.2)
Pseudomonas species 3 (3.4) 4 (1.0)
Acinetobacter species 3 (2.9) 4 (1.0)
Other Gram-negative bacteria 8 (9.1) 32 (8.4)
Gram-positive bacteria
Staphylococcus aureus 17 (19.3) 38 (9.9)
Streptococcus pneumoniae 0 (0) 8 (2.1)
Streptococcus suis 1 (1.1) 9 (2.4)
Other streptococci 0 (0) 28 (7.3)
Enterococci 1 (1.1) 12 (3.1)
Other Gram-positive bacteria 1 (1.0) 15 (3.5)
Note: some patients had two or more pathogens (435 patients; 471 isolates).
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users and patients with medical devices (e.g. prosthesis
and catheters) in our cohort as well as the high preva-
lence of Gram-negative pathogens in the environment of
tropical low-resource countries (Kaushik et al. 2012).
Data from BSI in Ugandan HIV patients described a high
prevalence of Streptococcus pneumoniae followed by
non-Typhoid Salmonella species and E. coli (Mayanja
et al. 2010). The relative paucity of Streptococcus pneu-
moniae in our population may be due to the intrinsic dif-
ﬁculty to cultivate this fastidious organism (especially
given the high rates of antibiotic use prior to sampling,
also in the community), a different study population (dif-
ferent level of CD4 cell counts, no children included) or
genuine differences in local microbiological ecology.
In the present study, cases in which the empiric treat-
ment did not cover the isolated pathogen were observed
in around 20% of BSI episodes, with S. aureus and
B. pseudomallei accounting for over half of them. It
remains to be assessed whether clinical practice guidelines
can be further improved or whether this could be over-
come by more accurate clinical evaluation prior to the
selection of empiric antibiotics. In-depth evaluation of
the adherence to the established guidelines should also be
performed. All these issues will be the focus of future
research.
We found overall high resistance rates of the key
pathogens to the commonly used antibiotics in both
HIV-positive and HIV-negative patients, especially
among the Gram-negative pathogens. This conﬁrms
previous ﬁndings from our hospital (Vlieghe et al.
2011b, 2012) and other settings in Cambodia (Ruppe
et al. 2009) and is in line with ﬁndings from other
countries in the region (Apisarnthanarak et al. 2007;
Chau et al. 2007). Other reports from Asia have shown
relatively lower resistance rates for the key pathogens
(Srifuengfung et al. 2005; Mootsikapun 2007; Deen
et al. 2012). More microbiological studies from a wide
range of settings should be conducted in this region, to
better deﬁne how rates of resistance vary across and
within countries and populations. This requires ongoing
efforts in implementing and strengthening diagnostic
microbiological capacities in the region.
In terms of broader public health implications, the
observed high resistance rates seriously compromise the
treatment options for community-acquired BSI in both
HIV-positive and HIV-negative patients in Cambodia.
Based on the microbiological data, more than 30% of
individuals with BSI in SHCH would require treatment
with expensive antibiotics that are usually not available
Table 3 Antibiotic resistance of key pathogens* according to
HIV status in SHCH, 2009–2011
HIV-positive
n (%)
HIV-negative
n (%)
Escherichia coli n = 26 n = 125
Amoxicillin 25 (96.2) 117 (93.3)
Cotrimoxazole 21 (80.8) 104 (83.2)
Ciproﬂoxacin 16 (61.5) 97 (77.6)
Amoxicillin-clavulanic acid 15 (57.7) 61 (48.8)
Ceftriaxone 12 (46.2) 58 (46.4)
Gentamicin 15 (57.7) 63 (50.4)
Amikacin 2 (7.7) 1 (0.8)
Meropenem 0 (0) 0 (0)
Salmonella typhi n = 2 n = 21
Amoxicillin 1 15 (71.4)
Cotrimoxazole 1 15 (71.4)
Ciproﬂoxacin 2 18 (85.7)
Ceftriaxone 0 0
Meropenem 0 0
Non-Typhoid Salmonella species n = 15 n = 7
Amoxicillin 12 (80.0) 6 (85.7)
Cotrimoxazole 9 (60.0) 4 (57.1)
Ciproﬂoxacin 6 (40.0) 3 (42.9)
Ceftriaxone 1 (6.7) 1 (14.3)
Meropenem 0 0
Staphylococcus aureus n = 14 n = 37
Oxacillin 4 (28.6) 7 (18.6)
Cotrimoxazole 4 (28.6) 3 (8.1)
Lincomycin 6 (42.9) 17 (46.0)
Ciproﬂoxacin 3 (21.4) 8 (21.6)
Vancomycin 0 0
*Only isolates from the ﬁrst episodes of bloodstream infection
were considered.
Table 4-a Appropriateness of empiric antibiotic treatment in 452 episodes of bloodstream infection in SHCH, 2009–2011
HIV-positive
n (%)
(n = 85)
HIV-negative
n (%)
(n = 367) p-value
Antibiotic matches the pathogen and susceptibility pattern 43 (50.6) 206 (56.1) 0.35
Antibiotic matches the pathogen but not the susceptibility pattern 25 (29.4) 77 (21.0) 0.11
Antibiotic does not match the pathogen 16 (18.8) 75 (20.4) 0.88
No empiric antibiotics prescribed 1 (1.2) 9 (2.5) 0.70
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urgent need for sustainable and affordable access to
broad-spectrum antibiotics such as carbapenem
antibiotics (e.g. for ESBL-positive E. coli), ceftazidime
and amoxicillin–clavulanic acid (i.e. for the treatment of
melioidosis) and vancomycin (i.e. for treatment of
invasive MRSA infections). This should go hand in hand
with the development of tools to optimise appropriate
use of antibiotics, including improved diagnostic capacity
or clinical scoring systems to predict antibiotic resistance
(Bowman et al. 2012) while antibiotic stewardship and
infection control programmes at local and national levels
will be essential to prevent the occurrence and spread of
antibiotic resistance.
Our study had a number of limitations. First, the
baseline characteristics of the HIV-positive and negative
patient groups were not truly comparable. HIV-negative
patients were older and had more underlying diseases,
especially diabetes, liver cirrhosis and chronic renal fail-
ure, making this group vulnerable to speciﬁc infections
(such as melioidosis) and worse outcomes. Therefore,
our ﬁndings may not be easily applicable to other
settings where HIV-negative patients have lower rates of
underlying diseases. In addition, our sample size was
fairly small, especially for HIV-positive patients, and the
antibiotic resistance data were based on routinely col-
lected data and not on prospective batch-testing of iso-
lates. Moreover, only short-term outcome data were
available. Although, based on ongoing supervision,
adherence to the clinical guidelines in the hospital
appeared to be good, we did not evaluate whether all
empiric antibiotic prescriptions were in line with the
clinical practice guidelines. Finally, we selected only
bacterial and not fungal or mycobacterial pathogens,
which are important pathogens in HIV-positive patients
(Archibald et al. 2000). A strength of our study relates
to the fact that data originate from a microbiological
surveillance setting where blood cultures were
systematically performed for all patients meeting the
criteria of sepsis. Moreover, patients came from differ-
ent areas of the country.
In conclusion, Salmonella choleraesuis and Staphylo-
coccus aureus were relatively more common in HIV-
positive patients than in HIV-negative patients and were
likely to recur. Resistance rates were high but not signiﬁ-
cantly different between the HIV-positive and HIV-
negative groups. The present data do not warrant
different empiric antibiotic regimens for HIV-positive vs.
HIV-negative patients. Further analysis of the mismatches
of empiric antibiotic prescriptions in SHCH is warranted
while the antibiotic resistance data suggest the need for
nationwide enhanced diagnostic capacity, access to
effective antibiotics and regulatory measures to contain
antibiotic resistance in Cambodia.
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